First-In-Human Phase I Study Of The Novel Celmod Agent Cc-92480 Combined With Dex In Pts With Rrmm

First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dex in pts with RRMM

International Myeloma Foundation

First-in-human phase I study of the novel CELMoD agent CC-92480

Results of Iberdomide in Combination with Dex and Daratumumab or Bortezomib in Patients with RRMM

International Myeloma Foundation

CC-92480: a novel CELMoD, in R/R myeloma

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Richardson on First-In-Human Phase 1 Trial With CC-92480 in R/R Myeloma

First clinical study of iberdomide, a CELMoD, in pts with relapsed/refractory multiple myeloma

International Myeloma Foundation

Updated analysis from the HORIZON study of melflufen in RRMM

Multiple Myeloma Hub

Evaluating Response Rates With CC-92480 Combination in Multiple Myeloma

Targeted Oncology

Preliminary data on mezigdomide plus dexamethasone and bortezomib in R/R multiple myeloma

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Richardson on the Mechanism of Action of CC-92480 in Multiple Myeloma

CC-92480 (mezigdomide) in R/R MM

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Richardson on the Next Steps With CC-92480 Research in Relapsed/Refractory Multiple Myeloma

Trial of Iberdomide, A Novel CELMoD, In Smoldering Multiple Myeloma | Nisha Joseph, MD | #ASH24

HealthTree Foundation for Multiple Myeloma

New Directions in Treating Multiple Myeloma in the Era of Novel Agents

Dana-Farber Cancer Institute

OPTIMISMM Trial: Pomalidomide in RRMM

Targeted Oncology

IMF Patient & Family Webinar - New Frontiers In Myeloma Care

International Myeloma Foundation

Novel drug conjugates for multiple myeloma treatment

VJHemOnc – Video Journal of Hematology & HemOnc

Results of single agent CC-90009 in R/R AML

Current and Future Directions for Novel Therapy for Multiple Myeloma: Paul G. Richardson, MD

Dana-Farber Cancer Institute